Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Net Cash Flow (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Net Cash Flow for 3 consecutive years, with -$7.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 19.21% to -$7.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$30.7 million through Dec 2025, down 343.09% year-over-year, with the annual reading at -$30.7 million for FY2025, 343.09% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$7.6 million at Mereo BioPharma, down from -$7.0 million in the prior quarter.
  • The five-year high for Net Cash Flow was $38.9 million in Q2 2024, with the low at -$9.7 million in Q1 2023.
  • Average Net Cash Flow over 3 years is -$2.6 million, with a median of -$7.8 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 601.39% in 2024, while the deepest fall reached 176.79% in 2024.
  • Over 3 years, Net Cash Flow stood at -$6.8 million in 2023, then plummeted by 39.34% to -$9.5 million in 2024, then grew by 19.21% to -$7.6 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$7.6 million, -$7.0 million, and -$7.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.